Czech Republic
France
Germany
Norway
Netherlands
Spain
Turkey
United KingdomUpdates
SUB-TYPE: CLASS 2 RECALL
CLASS 2 RECALL - DIOCTYL CAPSULES 100MG (100 PACK)
Reason: “UCB Pharma Ltd is recalling the above batch of product as a precautionary measure due to the presence of a foreign capsule being found in a sealed pack. The Marketing Authorisation Holder’s investigation concluded that this was the result of a product mix up during the manufacturing process.
MHRA drug alert date 18 January 2023
MHRA drug alert link:
Pip code | Product description | Livery | Batch Numbers |
0579409 | DIOCTYL CAP 100MG (100 PACK) | UCB PHARMA LTD | 322983D |
Further Information
For more information, medical or supply enquiries, please contact UCB Pharma Ltd on (+44) 01753 777100 or 0800 279 3177 (freephone) or by email at UCBCares.UK@ucb.com.
Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.
Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.
SUB-TYPE: CLASS 4 CAUTION IN USE
CLASS 4 CAUTION IN USE - BYLVAY 1200 MICROGRAMS HARD CAPSULES
Class 4 Drug Caution In Use - Bylvay 1200 Micrograms Hard Capsules
Albireo AB has informed the MHRA that there is a typographical error with the text on the side panel of the bottle label for a specific batch of Bylvay 1200 micrograms Hard Capsules.
MHRA drug alert date: 3rd January 2023
MHRA drug alert link:
Pip code | Product | Supplier | Affected Batches |
ALLIANCE DO NOT STOCK | BYLVAY 1200 MICROGRAMS HARD CAPSULES | ALBIREO AB | W067208E |
This is a caution in use only we are not accepting stock returns.
Further Information
For medical information and stock control queries please contact: medinfo@Albireopharma.com
SUB-TYPE: CLASS 4 CAUTION IN USE
Class 4 Medicines Defect Information: Galderma (U.K.) Limited, Etrivex 500 micrograms/g Shampoo
Galderma (U.K.) Limited has informed the MHRA that the patient information leaflet (PIL) packaged in specific batches of Etrivex Shampoo is missing safety information
Pip code | Product description | Supplier | Batch Numbers |
3281110 | ETRIVEX SHAMPOO 500MCG/G | GALDERMA | 0114291 0114277 0114252 |
This is a caution in use only we are not accepting stock returns - if any defective stock is found it should be returned directly to the manufacturer.
Further information
For more information, medical information queries or replacement PIL enquiries, please contact: medinfo.uk@galderma.com
For stock control queries, please contact: sales.uk@galderma.com
Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.
SUB-TYPE: CLASS 4 CAUTION IN USE
Class 4 Medicines Defect Information: ADVANZ Pharma Ltd, MacroBID 100mg Prolonged-Release Capsules
ADVANZ PHARMA has made the MHRA aware that certain batches of MacroBID 100mg Prolonged-Release Capsules have been packed with the incorrect Patient Information Leaflet (PIL).
MHRA drug alert date: 5th December 2022
Pip code | Product description | Supplier | Batch Numbers |
0941609 | MACROBID CAP 100MG | AMCO / MERCURY PHARMA | 21001 21002 21003 22001 22002 22003 22006 22007 |
This is a caution in use only we are not accepting stock returns - if any defective stock is found it should be returned directly to the manufacturer.
Further information
For further information, medical enquiries, stock information or request for printed copy of the associated SmPC, please contact telephone: + 44 (0) 208 5889 131 or via email: medicalinformation@advanzpharma.com.
Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.
SUB-TYPE: CLASS 4 CAUTION IN USE
Class 4 Medicines Defect Information: Lucis Pharma Ltd, Oxycodone Hydrochloride 10mg/ml oral solution
Lucis Pharma Ltd has informed the MHRA that there is a typographical error with text on the rear side of the outer packaging for Oxycodone Hydrochloride 10mg/ml Oral Solution.
MHRA drug alert date: 29 November 2022
Pip code | Product description | Supplier | Batch Numbers |
ALLIANCE DO NOT SOCK | OXYCODONE HYROCHLORIDE 10MG/ML ORAL SOLUTION | LUCIS PHARMA LTD | 21050004 22080005 |
This is a caution in use only we are not accepting stock returns - if any defective stock is found it should be returned directly to the manufacturer.
Further information
For medical information and stock control queries please contact: enquiries@lucispharma.co.uk.
Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.
SUB-TYPE: CLASS 4 CAUTION IN USE
Class 4 Medicines Defect Information: Martindale Pharma Venlafaxine 300mg XL Prolonged release tablets
Martindale Pharma has made the MHRA aware that the GTIN in the 2D barcode and the printed variable data represents the branded version of the product (Venlalic® XL 300 mg prolonged-release tablets).
MHRA drug alert date: 16 November 2022
Pip code | Product description | Supplier | Batch Numbers |
8047318 1257559 8045320 | VENLAFAXINE XL TAB 300MG | MARTINDALE PHARMA | LC69391 |
This is a caution in use only we are not accepting stock returns - if any defective stock is found it should be returned directly to the manufacturer.
Further Information
For further information, medical enquiries and stock information, contact: Licensed@ethypharm.com
Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.
SUB-TYPE: CLASS 4 CAUTION IN USE
Class 4 Medicines Defect Information: PRENOXAD 1MG/ML INJECTION
Macarthys Laboratories (trading as Martindale Pharma, an Ethypharm Group Company), has notified the MHRA of a limited number of Prenoxad packs in a batch marketed in France with missing needles.
MHRA drug alert date: 10th November 2022
Pip code | Product description | Supplier | Batch Numbers | ||||||||||||||||||||||||
3797131 | PRENOXAD 1MG/ML INJECTION | ETHYPHARM GROUP COMPANY |
|
This is a caution in use only we are not accepting stock returns - if any defective stock is found it should be returned directly to the manufacturer.
Further Information
For more information on licensed stock and resupply queries for the licensed presentation, please contact licensed@ethypharm.com; telephone number: 0800 028 7933.
For medical information queries and all other enquiries, please contact medinfo@ethypharm.com; telephone number 01277 266 600.
Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.
SUB-TYPE: COMPANY-LED RECALL
Company Led Recall-Activa Thigh Length Open Toe Hosiery class 2 XL size
L&R medical have informed us that on the affected batch of Activa Thigh Length Open Toe Hosiery XL the product inside the packaging is Small and not Extra Large
MHRA drug alert link: N/A
PIP CODE | DESCRIPTION | SUPPLIER | AFFECTED BATCHES |
2590883 | ACTIVA T/L O/T C2 SND XL | L&R MEDICAL UK LTD | 221909 |
Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies
Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.
For more information please contact L&R MEDICAL UK LTD
Quality&Regulatory@uk.lrmed.com
SUB-TYPE: CLASS 3 RECALL
Class 3 Recall - Mebeverine hydrochloride 135mg Film-coated Tablets
Medreich Plc UK is recalling the above batch as a precautionary measure due to out of specification results for tablet dissolution during routine product release testing.
MHRA drug alert date: 27th October 2022
Pip code | Product description | Supplier | Batch Numbers |
1152123 | MEBEVERINE TAB 135MG | MEDREICH PLC | B11539 |
1037514 | MEBEVERINE TAB 135MG | MEDREICH PLC | B11539 |
8113110 | OTCD MEBEVERINE TAB 135MG | MEDREICH PLC | B11539 |
Further Information
For more information or supply enquiries, please contact Medreich PLC at cs_team@medreich.co.uk or by phone at 0208 831 1580, 0208 831 1511 or 0208 831 1509
For medical information queries, please contact pharmacovigilance@medreich.com
Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.
SUB-TYPE: CLASS 4 CAUTION IN USE
Class 4 Medicines Defect Information: Recordati Rare Diseases, Pedea 5 mg/ml solution for injection
Recordati Rare Diseases T/A Recordati Rare Diseases UK Ltd has made the MHRA aware that specific batches of Pedea 5 mg/ml solution for injection have been packaged with the incorrect Product Information Leaflet (PIL).
MHRA drug alert date: 25th October 2022
MHRA drug alert link:
Pip code | Product description | Supplier | Batch Numbers |
ALLIANCE DO NOT STOCK | PEDEA 5 MG/ML SOLUTION FOR INJECTION, 4 AMPOULES | RECORDATI RARE DISEASES T/A RECORDATI RARE DISEASES UK LTD | PD0G24E-07 PD0G24E-10 PF0G04E-03 |
This is a caution in use only we are not accepting stock returns - if any defective stock is found it should be returned directly to the manufacturer.
For further information, including medical enquiries and stock information, please contact:
Recordati Rare Diseases UK Ltd (local representative, WDA(H): 15720) on Tel: +44 (0)1491 414333 or +33 1 47 73 64 58 or email: RRDmedinfo@recordati.com
Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to hospital pharmacists and pediatric doctors and nurses working in hospital setting for information.